Exhibit 99.1

For Further Information:
- ------------------------

Human Pheromone Sciences, Inc.
84 West Santa Clara Street, Suite 720
San Jose, CA  95113
(408) 938-3030
Contacts:         William P. Horgan
                  Chairman, CEO


              Human Pheromone Sciences, Inc. and Rubinson End Talks

San Jose, California,  November 16, 2005--Human Pheromone Sciences, Inc. (OTCBB-
EROX)  today  announced  that the  Company  and  Rubinson  and  Associates  have
terminated  their  previously  announced  term sheet for the sale of  previously
unissued and unregistered shares to Rubinson and Associates.

A  spokesperson  for the Company  indicated that it is now free to actively seek
alternative financing opportunities.

Human Pheromone Sciences, Inc. is a technology-based  company which develops and
markets mood  enhancing  compounds for use in consumer  products.  The Company's
proof-of concept products included prestige-priced fragrances and toiletries and
consumer products sold under the Natural Attraction(R),  REALM(R), innerREALM(R)
and EROX(R) trademarks.  The Company also licenses its proprietary technology to
other companies for inclusion in their products for direct sale to the consumer.
These  products  contain  human  pheromones,  the use of which is covered  under
United States and foreign  patents.  Scientific and consumer  studies have shown
that the Company's human pheromones  positively  impact on the moods,  attitudes
and  emotions  of  wearers.   Further   information  is  available  on  line  at
www.erox.com.

The statements in this news release may contain forward-looking  statements that
involve  risks and  uncertainties  that  could  cause  results  to  differ  from
predicted  results.  Further  information  on  factors  that  could  affect  the
Company's  results is detailed in the Company's annual report to shareholders on
Form 10-KSB for the year ended  December  31, 2004 as filed with the  Securities
and Exchange  Commission  and the Form 10QSB for the three and nine months ended
September 30, 2005. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements.



                                       6